Quince Therapeutics, Inc. (QNCX): Depreciation & Amortization
$142.0K
Year ended 2025-12-31
$152.0K
Trailing 12 months to 2026-06-30
-11.4%
3-year compound annual growth
-15.6%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $142.0K | -23.7% | 2026-04-10, From 2025-01-01 |
| 2024-12-31 | $186.0K | -42.2% | 2026-04-10, From 2024-01-01 |
| 2023-12-31 | $322.0K | +57.8% | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | $204.0K | -40.7% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $344.0K | +3.6% | 2023-03-15, From 2021-01-01 |
| 2020-12-31 | $332.0K | +76.6% | 2022-03-01, From 2020-01-01 |
| 2019-12-31 | $188.0K | +268.6% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $51.0K | n/a | 2021-03-01, From 2018-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | 2025-12-31 | $142.0K | -23.7% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $664.0K | -6.2% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $537.0K | -62.8% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $58.6K | -27.9% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $699.0K | +19.1% |
| Armata Pharmaceuticals, Inc. (ARMP) | 2024-12-31 | $1.32M | +36.3% |
| Zura Bio Ltd (ZURA) | 2025-12-31 | $49.0K | +444.4% |
| Artiva Biotherapeutics, Inc. (ARTV) | 2025-12-31 | $2.60M | +6.8% |
| Elutia Inc. (ELUT) | 2025-12-31 | $2.79M | -19.3% |
Compare QNCX, ATYR, SRZN, ACOG side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗